Abstract 565P
Background
Acquired genomic alternations are known mechanisms of resistance to osimertinib in patients with advanced epidermal growth factor receptor (EGFR) positive non-small cell lung cancer (NSCLC). Addition of genome-guided targeted therapy (GGTT) to osimertinib may improve treatment outcomes.
Methods
This retrospective study reviewed 226 metastatic EGFR mutation positive NSCLC patients who received systemic therapy after failing osimertinib. Primary endpoints include time-to-treatment failure (TTF) and overall survival (OS) from post-osimertinib failure.
Results
Total of 68 patients had genomic analysis for osimertinib resistance and 21 (30%) had targetable genomic alternations. Out of which, 17 received osimertinib plus GGTT (13 MET amplification, 2 ALK rearrangement, 1 RET rearrangement and 1 BRAF V600E mutation) and 209 patients received chemotherapy. Median follow-up were 10.0 and 30.1 months for GGTT and chemotherapy group respectively. The GGTT group achieved significantly longer TTF (not reached [NR] vs 5.1 months, HR 0.19, 95% CI 0.08-0.48, p<0.001) and OS (NR versus 10.5 months, HR 0.27, 95% CI 0.09-0.86, p=0.026) compared to those receiving chemotherapy. These results remained significant after multivariate analysis (Table). In subgroup analysis, TTF of GGTT group was superior to chemotherapy alone (n=148) (NR versus 4.5 months, HR 0.18, p<0.001), chemotherapy plus osimertinib (n=41) (NR versus 6.2 months, HR 0.23, p=0.003) and chemotherapy plus anti-PD(L)1 plus anti-VEGF (n=20) (NR versus 6.3 months, HR 0.25, p=0.009), respectively. Table: 565P
Time to treatment failure | Overall survival | |||||||
Univariate | Multivariate | Univariate | Multivariate | |||||
HR | P-value | HR | P-value | HR | P-value | HR | P-value | |
Age (>65) | 0.95 | 0.74 | 1.16 | 0.35 | ||||
Gender (Female) | 0.94 | 0.43 | 0.85 | 0.046 | ||||
PS (>1) | 1.67 | 0.014 | 1.75 | 0.009 | 2.54 | <0.001 | 2.73 | <0.001 |
EGFR (ex19 del vs L858R)* | 1.03 | 0.83 | 0.98 | 0.91 | ||||
Line of Osimertinib (>1) | 1.51 | 0.037 | 1.40 | 0.10 | ||||
CNS metastases | 1.09 | 0.55 | 1.28 | 0.12 | ||||
Liver metastases | 1.30 | 0.05 | 1.36 | 0.05 | 1.42 | 0.037 | 1.50 | 0.016 |
Bone metastases | 1.92 | 0.001 | 1.71 | 0.011 | ||||
Therapy (GGTT) | 0.19 | <0.001 | 0.22 | 0.001 | 0.27 | 0.026 | 0.24 | 0.015 |
∗2 patients with EGFR mutations other than exon 19 deletion and exon 21 L858R mutation excluded from analysisCNS, central nervous system; EGFR, epidermal growth factor receptor; PS, performance status
Conclusions
The combination of GGTT and osimertinib improves TTF and OS in EGFR mutation positive NSCLC patients failing osimertinib. Future prospective comparative study is warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M.S.C. Li: Financial Interests, Personal, Advisory Board: AstraZeneca, Amgen, Takeda, Pfizer, Guardant Health; Financial Interests, Personal, Research Grant: Gilead, Takeda; Financial Interests, Personal, Invited Speaker: BMS, Amgen, ACE Oncology, AstraZeneca, Novartis, Takeda. K.W.C. Lee: Financial Interests, Personal, Full or part-time Employment: ACT Genomics; Financial Interests, Personal, Invited Speaker: AstraZeneca, Roche, Takeda, Janssen, C-stone; Financial Interests, Personal, Advisory Board: Merck, Janssen, Novartis; Financial Interests, Personal, Stocks or ownership: ACT Genomics, Prenetics. H.H.F. Loong: Financial Interests, Institutional, Invited Speaker: Boehringer Ingelheim, MSD; Financial Interests, Personal, Invited Speaker: Eli Lilly, Illumina, Bayer, Guardant Health; Financial Interests, Personal, Advisory Board: Novartis, Takeda. T.S.K. Mok: Financial Interests, Personal, Advisory Board: AbbVie, Amgen, Berry Oncology, Boehringer Ingelheim, C4 Therapeutics, D3 Bio, Eisai, G1 Therapeutics, Gritstone Oncology, GeneDecode, Hutchmed, Incyte Corporation, IQVIA, Lilly, Lunit, MSD, Novartis, Puma Biotechnology, Roche, SFJ Pharmaceuticals, Vertex Pharmaceuticals, Yuhan Corporation, ACEA Pharma, AstraZeneca, Blueprint, BMS, Covidien LP, Curio Science, Daiichi Sankyo, Fishawack Facilitate, Gilead Sciences, Guardant Health, Hengrui, Ignyta, Inivata, Janssen, Loxo Oncology, Merck Serono, Mirati, Origimed, Pfizer, Sanofi Aventis, Takeda, Virtus; Financial Interests, Personal, Research Grant: AstraZeneca, BMS, Pfizer, Roche, Novartis, SFJ Pharmaceuticals, MSD, G1 Therapeutics, Takeda, XCovery, Merck Serono; Financial Interests, Personal, Invited Speaker: ACEA Pharmaceuticals, Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Fishawack Facilitate, Janssen, Lucence Health, Medscape LLC, MSD, OrigiMed, PeerVoice, Pfizer, Research to Practice, Sanofi-Aventis, Liangyihui Network Technology, Takeda, Alpha Biopharma, Amoy Diagnostics, BeiGene, BMS, Daz Group, InMed Medical Communication, Lilly, MD Health Brazil, Merck, Novartis, P. Permanyer, Physicians' Education Resource, PrIME Oncology, Roche, Shanghai BeBirds, Taiho, Touch Independent Medical Education; Financial Interests, Personal, Leadership Role: AstraZeneca, Lunit, ATORG, CSCO, HKCTS, HutchMed, ASCO, CLCRF, HKCF; Financial Interests, Personal, Stocks or ownership: Aurora Tele-Oncology, Hutchmed, ACT Genomic. All other authors have declared no conflicts of interest.
Resources from the same session
193P - Impact of coronavirus disease 2019 on patients with unresectable hepatocellular carcinoma treated with atezolizumab/bevacizumab
Presenter: Hongjae Chon
Session: Poster Display
Resources:
Abstract
194P - Real-world outcomes of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus chemotherapy as first-line treatment in advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS≤5
Presenter: Qi Xu
Session: Poster Display
Resources:
Abstract
195P - Ferroptosis signatures in pancreatic ductal adenocarcinomas and their role in patient survival: A translational unsupervised clustering analysis
Presenter: Quoc-Huy Trinh
Session: Poster Display
Resources:
Abstract
196P - Clinical significance of circulating CD8+ and CD4+ T cell proliferation in advanced gastric cancer receiving first-line chemotherapy
Presenter: In-Ho Kim
Session: Poster Display
Resources:
Abstract
197P - Treatment patterns and clinical outcomes of patients with unresectable advanced or metastatic (UAM) gastric/gastroesophageal junction adenocarcinoma (GA/GEJA) in China: A multicenter real-world study
Presenter: Yanqiao Zhang
Session: Poster Display
Resources:
Abstract
198P - Effectiveness of lenvatinib in patients with unresectable hepatocellular carcinoma: A multicenter observational study in Japan
Presenter: Namiki Izumi
Session: Poster Display
Resources:
Abstract
199P - Efficacy of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus: A randomized, open-label, phase II trial
Presenter: Yuexiao Qi
Session: Poster Display
Resources:
Abstract
200P - Prognosis of patients with hepatocellular carcinoma treated with transarterial chemoembolization: Development and validation of the ALFP score
Presenter: Baocuo Gong
Session: Poster Display
Resources:
Abstract
201P - A phase II study of serplulimab (a programmed death-1 inhibitor) with or without HLX04 (a bevacizumab biosimilar) for the treatment of advanced hepatocellular carcinoma
Presenter: Zhenggang Ren
Session: Poster Display
Resources:
Abstract
202P - Comparison of liver injury after transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy for intermediate and advanced hepatocellular carcinoma
Presenter: Yongru Chen
Session: Poster Display
Resources:
Abstract